Neurogen Biomarking

We just published a comprehensive breakdown on what actually happens during an at-home memory health test: how it works, what you receive, and why early clarity matters. If you’ve been considering testing for yourself or someone you love, this is a helpful place to start. Read the full blog here: https://lnkd.in/gyCNDnjg

Thank you, Tia Graham and WDET 101.9 FM, for the roundup story about the power that blood biomarker tests are having in improving early detection of Alzheimer’s disease. Click on the link to hear our CEO and Founder, Rany Aburashed DO, share his insights on these advances and Neurogen’s mission to make them more accessible to everyone. #earlydetection #alzheimersdemetia #bloodbiomarkers #healthequity https://lnkd.in/gbBsUCG6

Today, Neurogen Biomarking announced a broad partnership agreement with Tasso, Inc. that will incorporate it's virtually painless blood collection technology into our platform. The collaboration positions Neurogen at the forefront of globally building a scalable, home-based model for Alzheimer’s-related biomarker testing and cognitive-health services. Read the full press release here: https://lnkd.in/gQrXcsSh #Alzheimers #Earlydetectiontesting #HealthcareInnovation #HealthEquity

Michiganders! Tune in! Rany Aburashed DO "Dr. Rany" will be live with Tia Graham on "The Metro" WDET 101.9 FM around 11am EST today — discussing early detection for Alzheimer’s dementia and our innovative ecosystem for brain health care.

Memory health is one of today’s most important, and most misunderstood, topics. Too often, people wait until symptoms appear to take action. Biomarkers are changing that story. These measurable signals in the body can reveal brain changes years before memory loss begins. At Neurogen Biomarking, we’re making this science accessible and actionable, helping people take control of their memory health with clarity and confidence. Learn how biomarkers are reshaping early detection and empowering proactive brain health. Read our full blog here: https://lnkd.in/gwMGAjxu

From medicine to mission, our CEO Dr. Rany Aburashed has just been featured in Forbes. The story dives deep into his journey through healthcare, innovation, and leadership and how those experiences led to the creation of Neurogen Biomarking, a company built to change the way the world approaches Alzheimer’s. Read the full Forbes article here: 🔗 https://lnkd.in/gcCcXUSq

Are you interested in learning exactly how our blood test works and why it’s so effective? Please read our newest blog that will answer all of your questions! https://lnkd.in/gPe8T2Bs

HERE WE COME, DEARBORN, MI! Help us spread the word! On Saturday, November 8, Neurogen Biomarking will host our 4th “Capturing Memories” Community Brain Health Day at Insight Hospital and Medical Center Dearborn — for people over 50 with cognitive concerns, we are offering a FREE digital memory screening and an advanced blood biomarker test (P-tau 217) that detect early indicators of Alzheimer’s years before symptoms become severe. Nearly 500 people have been empowered to take charge of their brain health at our other events — and we’re excited to bring this opportunity to Dearborn. Join us and share this opportunity with others. Together, we can change the future of brain health. Register today at www.mybrainday.com See more details below. #EarlyDetection #AlzheimersAwareness #BrainHealth #Dementia #MildCognitiveImpairment #Ptau217 #DigitalCognitiveAssessment #Telehealth #HealthEquity

We’re honored to be featured in Meditech Wire, highlighting how our innovation can better serve families navigating Alzheimer’s concerns. At Neurogen Biomarking, we deeply resonate with this story because behind every test is a family searching for clarity, compassion, and confidence in the future of their loved ones. Read the full article linked below. https://lnkd.in/gSaSNSuh

We’re honored that Alzforum has featured Neurogen’s work on the evolving role of plasma p-tau217 in Alzheimer’s detection. The article highlights how our remote-first model — combining remote blood testing and cognitive assessments with neurologist-led telehealth consultations — is helping shorten the time from cognitive concern to clinical action, while ensuring results are interpreted responsibly by medical experts. With plasma p-tau217 orders doubling every 4–8 months, reliable, patient-centered tools have never been more important. Neurogen is committed to supporting clinicians and patients alike in navigating this new frontier of Alzheimer’s detection. Read the full article here: https://lnkd.in/gJ7kFDe6